Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPT567 in Advanced Solid Tumors
NCT06779851Phase 1Terminated
- Sponsor
- Bright Peak Therapeutics
- Start
- Oct 2024
- Primary completion
- Jan 2026
- Modality
- Immunomodulatory ADCs, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPT567 in solid tumor (2 arms), sponsored by Bright Peak Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose or Maximum Administered Dose at 28 days and 1 more. Started Oct 2024; status: terminated.
02
Drugs
BPT567
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06779851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06779851.